Prey, S <br/><br/>
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.  [electronic resource] 

 -  The British journal of dermatology  Nov 2012 
 - 1138-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2133.2012.11186.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Benzamides<br/>Double-Blind Method<br/>Female<br/>Fibrosis--drug therapy<br/>Humans<br/>Imatinib Mesylate<br/>Male<br/>Middle Aged<br/>Piperazines--therapeutic use<br/>Platelet-Derived Growth Factor--metabolism<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Quality of Life<br/>Scleroderma, Diffuse--drug therapy<br/>Skin--pathology<br/>Transforming Growth Factor beta--metabolism<br/>Treatment Outcome